Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has experienced a rise in its stock price by 1.57 compared to its previous closing price of 109.57. However, the company has seen a gain of 4.55% in its stock price over the last five trading days. prnewswire.com reported 2024-09-16 that Phase 2 updated results for zanidatamab in HER2-positive mGEA included a confirmed objective response rate (cORR) of 84%, duration of response (DoR) of 18.7 months, median progression-free survival (mPFS) of 15.2 months and a Kaplan-Meier–es ti mated overall survival (OS) of 59% at 30 months DUBLIN, Sept. 16, 2024 /PRNewswire/ — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced updated data, including median progression-free survival (mPFS) and overall survival (OS) findings, from the Phase 2 trial of zanidatamab, an investigational dual HER2-targeted bispecific antibody, in combination with chemotherapy as first-line treatment for patients with HER2-expressing advanced or metastatic gastroesophageal adenocarcinoma (mGEA).
Is It Worth Investing in Jazz Pharmaceuticals plc (NASDAQ: JAZZ) Right Now?
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has a higher price-to-earnings ratio of 19.88x compared to its average ratio, The 36-month beta value for JAZZ is at 0.58. Analysts have varying views on the stock, with 12 analysts rating it as a “buy,” 4 rating it as “overweight,” 5 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for JAZZ is 59.60M, and currently, shorts hold a 3.17% of that float. The average trading volume for JAZZ on September 20, 2024 was 696.29K shares.
JAZZ’s Market Performance
JAZZ stock saw a decrease of 4.55% in the past week, with a monthly decline of -3.20% and a quarterly a decrease of 3.66%. The volatility ratio for the week is 2.28%, and the volatility levels for the last 30 days are 2.20% for Jazz Pharmaceuticals plc (JAZZ).. The simple moving average for the past 20 days is 0.35% for JAZZ’s stock, with a -3.07% simple moving average for the past 200 days.
Analysts’ Opinion of JAZZ
Many brokerage firms have already submitted their reports for JAZZ stocks, with Goldman repeating the rating for JAZZ by listing it as a “Buy.” The predicted price for JAZZ in the upcoming period, according to Goldman is $169 based on the research report published on June 05, 2024 of the current year 2024.
Robert W. Baird, on the other hand, stated in their research note that they expect to see JAZZ reach a price target of $160. The rating they have provided for JAZZ stocks is “Outperform” according to the report published on January 03rd, 2024.
UBS gave a rating of “Neutral” to JAZZ, setting the target price at $135 in the report published on November 27th of the previous year.
JAZZ Trading at 0.89% from the 50-Day Moving Average
After a stumble in the market that brought JAZZ to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -18.99% of loss for the given period.
Volatility was left at 2.20%, however, over the last 30 days, the volatility rate increased by 2.28%, as shares sank -2.68% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +8.86% upper at present.
During the last 5 trading sessions, JAZZ rose by +4.55%, which changed the moving average for the period of 200-days by -6.57% in comparison to the 20-day moving average, which settled at $110.74. In addition, Jazz Pharmaceuticals plc saw -9.52% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at JAZZ starting from Henderson Mary Elizabeth, who sale 1,410 shares at the price of $108.30 back on Sep 06 ’24. After this action, Henderson Mary Elizabeth now owns 14,531 shares of Jazz Pharmaceuticals plc, valued at $152,703 using the latest closing price.
Henderson Mary Elizabeth, the Officer of Jazz Pharmaceuticals plc, proposed sale 2,691 shares at $110.00 during a trade that took place back on Sep 06 ’24, which means that Henderson Mary Elizabeth is holding shares at $296,010 based on the most recent closing price.
Stock Fundamentals for JAZZ
Current profitability levels for the company are sitting at:
- 0.17 for the present operating margin
- 0.78 for the gross margin
The net margin for Jazz Pharmaceuticals plc stands at 0.1. The total capital return value is set at 0.07. Equity return is now at value 10.84, with 3.49 for asset returns.
Based on Jazz Pharmaceuticals plc (JAZZ), the company’s capital structure generated 0.6 points at debt to capital in total, while cash flow to debt ratio is standing at 0.19. The debt to equity ratio resting at 1.52. The interest coverage ratio of the stock is 2.25.
Currently, EBITDA for the company is 1.3 billion with net debt to EBITDA at 3.46. When we switch over and look at the enterprise to sales, we see a ratio of 2.91. The receivables turnover for the company is 5.6for trailing twelve months and the total asset turnover is 0.34. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.25.
Conclusion
In conclusion, Jazz Pharmaceuticals plc (JAZZ) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
